Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Processa Pharmaceuticals Inc
PCSA
Healthcare
Biotechnology
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC...
treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PCSA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 28, 2024 8:15pm
Processa Pharmaceuticals Provides Product Pipeline and Finan
News; $PCSA Processa Pharmaceuticals Provides Product Pipeline and Financial UpdatePhase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 19, 2024 6:15pm
InvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ:
News; $PCSA InvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-IriProcessa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage
...more
(9)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 03, 2024 3:31am
Processa Pharmaceuticals, Inc. (PCSA): Advancing Next Genera
https://beyondspx.com/2024/08/02/processa-pharmaceuticals-inc-pcsa-advancing-next-generation-chemotherapy-treatments-with-regulatory-science-approach/
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jul 30, 2024 9:15am
RE:PCSA.....FDA cleared for IND...$3.70
pardon me ....$2.70 not $3.70
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 30, 2024 9:14am
PCSA.....FDA cleared for IND...$3.70
Ripping in PM trading...... I tend to think that this is a "good news / Bad news situation. Here is the Bad news which is what this Price action & volume is all about......read it! sec.gov
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on May 06, 2024 4:45pm
Processa Pharmaceuticals to Participate in the EF Hutton Ann
NEWS: $PCSA Processa Pharmaceuticals to Participate in the EF Hutton Annual Global ConferenceHANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 25, 2024 10:15am
US Companies Moving the Markets, Morning edition
Thu, Ap
BREAKING NEWS: $PCSA US Companies Moving the Markets, Morning edition Thu, Apr 25, 2024 as of 10.00 am ETA look at the top 10 most actives in the United States Safe @ Green Holdings Corp. (SGBX) rose
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 21, 2024 8:15am
New Press Release - Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 14, 2024 1:00pm
New Press Release - Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 06, 2024 8:30am
New Press Release - Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
read article.
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 02, 2024 11:45am
InvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ:
News; $PCSA InvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $7M Public OfferingProcessa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 01, 2024 4:22pm
New Press Release - Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
HANOVER, MD, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
read article.
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 26, 2024 5:30pm
What's Going On With Anti Cancer Focused Processa Pharmaceut
News; $PCSA What's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today? | BenzingaThursday,@Processa Pharmaceuticals Inc@(NASDAQ:PCSA) shares closed 148.8% higher at $5.10
...more
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 26, 2024 12:35pm
RE:RE:RE:RE:PCSA..... go ahead .... I dare ya to Chase !
JUst to be perfectly clear..... I was wrong about my AH prediction on PCSA.....It actually went alot higher than I thought it would....my bad. But in the end .... I was totally correct on my P.O call
...more
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 26, 2024 9:10am
PCSA....Well...well...well. What do ya know?
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering 2024-01-26 06:04 ET - News Release HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa
...more
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight